Celcuity’s (CELC) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note released on Friday morning,Benzinga reports. Needham & Company LLC currently has a $23.00 price objective on the stock.

A number of other brokerages have also recently commented on CELC. Leerink Partners started coverage on Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective for the company. Leerink Partnrs upgraded shares of Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Stifel Nicolaus raised their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $29.17.

Celcuity Price Performance

CELC stock opened at $12.66 on Friday. Celcuity has a 1 year low of $11.51 and a 1 year high of $22.19. The stock has a market capitalization of $468.80 million, a PE ratio of -4.85 and a beta of 0.76. The company’s 50-day moving average is $15.15 and its 200-day moving average is $16.04. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Celcuity during the 3rd quarter worth approximately $33,000. Prospera Private Wealth LLC bought a new stake in Celcuity during the third quarter worth $35,000. Values First Advisors Inc. purchased a new position in Celcuity in the third quarter worth $86,000. Quest Partners LLC grew its stake in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares during the period. Finally, SG Americas Securities LLC bought a new position in Celcuity in the 3rd quarter valued at $119,000. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.